Professional development and education
Kathryn Edwards, MD
Vanderbilt University School of Medicine
Nashville, TN, United States
Disclosure(s): BioNet: Consultant (Ongoing); CEPI: Advisor or Review Panel Member (Ongoing); IBM: Consultant (Ongoing); Merck: Advisor or Review Panel Member (Ongoing); Moderna: Advisor or Review Panel Member (Ongoing); Novavax: Advisor or Review Panel Member (Ongoing); Pfizer: Advisor or Review Panel Member (Ongoing); Roche: Advisor or Review Panel Member (Ongoing); Sanofi: Advisor or Review Panel Member (Ongoing); Seqirus: Advisor or Review Panel Member (Ongoing); X-4 Pharma: Advisor or Review Panel Member (Ongoing)
Lisa Imundo, MD
New York Presbyterian Hospital - Columbia Campus
New York, NY, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Pediatric rheumatology patients are a vulnerable population often at high risk for infection due to their underlying disease or secondary to immunosuppressive medications. It is important to recognize when it is appropriate to vaccinate versus when to hold off vaccination in this population. Additionally, response to vaccines may be different due to patients being on immunosuppressive medications. The ACR published vaccination guidelines for patients with rheumatic disease in 2022, as did the EULAR in 2021. This session will feature current evidence around vaccination using the existing guidelines as a framework in pediatric rheumatology. The safety and immunogenicity of vaccines will also be reviewed.
Speaker: Lisa Imundo, MD – New York Presbyterian Hospital - Columbia Campus
Speaker: Kathryn Edwards, MD – Vanderbilt University School of Medicine
